Orforglipron Gets EU Committee Backing: What the Foundayo Recommendation Means
EMA advisers recommend Foundayo for adult weight management and type 2 diabetes. Understand the evidence...
Omnipod Pod Correction: Under-Delivery Risk and What Users Should Check
Omnipod pod correction guide covering affected products, insulin under-delivery, high glucose, DKA risk, lot checks...
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar
New Research Confirms GLP-1 Medications Protect the Heart, Not Just Blood Sugar: cardiovascular outcome trial...
Levemir Withdrawal in the UK: November Switching Deadline Explained
A new UK alert asks services to complete Levemir switches by 30 November 2026. Here...
Insulin cost caps help some commercially insured adults, but many insulin users remain unprotected
New Diabetes Care research explains why state insulin cost caps help some people, but leave...
Inflammation and Heart-Failure Risk in Type 2 Diabetes: What the Look AHEAD Study Found
New Look AHEAD findings connect IL-6 with heart-failure risk in type 2 diabetes, but do...
Human vs Analogue Insulin in Young People With Type 1 Diabetes: What the HumAn-1 Trial Found
The HumAn-1 trial found no clear CGM advantage for glargine over usual-care human insulin regimens...
HIIT for Diabetes: Benefits, Limits, and Safety Checks
HIIT may help fitness and glucose for some people with diabetes, but it is not...
Heart Health and Type 2 Diabetes: What New Research Says About Modern Diabetes Medications
A new review of 133 randomized trials explains how modern type 2 diabetes medication classes...